## **Core Concept**
Crohn's disease is a type of inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. Biological therapies, also known as biologics, are a class of medications that target specific proteins involved in the inflammatory process. They have become a cornerstone in the management of moderate to severe Crohn's disease.

## **Why the Correct Answer is Right**
The correct answer, **Infliximab**, is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha), a key cytokine involved in the inflammatory cascade of Crohn's disease. By binding to TNF-alpha, infliximab reduces inflammation and prevents further tissue damage. Infliximab has been shown to induce and maintain clinical remission in patients with Crohn's disease and is considered an established biological therapy for this condition.

## **Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because, although it might represent another biologic agent, it is not specified and does not match the established therapy for Crohn's disease as described.
* **Option B:** This option is incorrect for similar reasons; without specification, it's hard to assess, but it's not the established therapy.
* **Option D:** This option is incorrect because, like options A and B, without specification, it cannot be considered the established biological therapy for Crohn's disease.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **Infliximab** and other TNF-alpha inhibitors (e.g., adalimumab, certolizumab) are effective in treating Crohn's disease but can increase the risk of infections and potentially reactivate latent tuberculosis. Screening for TB before starting these medications is a critical step in patient management.

## **Correct Answer:** . Infliximab